Here, we describe the construction, characterization, and use of VACV strains co-expressing murine Interleukin 2 (mIL2) and tumor-associated antigen (TAA)-derived epitopes as potential therapeutic agents against murine mammary carcinoma. The gene discussed is IL2; the disease is breast carcinoma.